BECTON, DICKINSON AND COMPANY (NYSE:BDX) Files An 8-K Financial Statements and Exhibits

BECTON, DICKINSON AND COMPANY (NYSE:BDX) Files An 8-K Financial Statements and Exhibits
Item 9.01 Financial Statements and Exhibits

Story continues below

(d) Exhibits.

1.1

Underwriting Agreement, dated May 17, 2018, by and among Becton, Dickinson and Company, Barclays Bank PLC and the several other underwriters named in Schedule I thereto.

1.2

Underwriting Agreement, dated May 17, 2018, by and among Becton, Dickinson and Company, Barclays Bank PLC and the several other underwriters named in Schedule I thereto.

INDEX TO EXHIBITS

Exhibit Number

Description

Underwriting Agreement, dated May 17, 2018, by and among Becton, Dickinson and Company, Barclays Bank PLC and the several other underwriters named in Schedule I thereto.

Underwriting Agreement, dated May 17, 2018, by and among Becton, Dickinson and Company, Barclays Bank PLC and the several other underwriters named in Schedule I thereto.


BECTON DICKINSON & CO Exhibit
EX-1.1 2 s002273-ex1_1.htm EXHIBIT 1.1 Exhibit 1.1   EXECUTION VERSION   Becton,…
To view the full exhibit click here

About BECTON, DICKINSON AND COMPANY (NYSE:BDX)

Becton, Dickinson and Company (BD) is a global medical technology company engaged in the development, manufacture and sale of a range of medical supplies, devices, laboratory equipment and diagnostic products. The Company operates through two segments: BD Medical and BD Life Sciences. The BD Medical segment produces an array of medical technologies and devices that are used to help improve healthcare delivery in a range of settings. BD Medical consists of various business units, including diabetes care, medication and procedural solutions, medication management solutions and pharmaceutical systems. The BD Life Sciences segment provides products for the safe collection and transport of diagnostics specimens, and instruments and reagent systems to detect a range of infectious diseases, healthcare-associated infections and cancers. The Company’s BD Life Sciences segment consists of various business units, including preanalytical systems, diagnostic systems and biosciences.

An ad to help with our costs